Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells

Melanoma is the most aggressive skin cancer and its incidence is gradually increasing worldwide. Patients with metastatic melanoma have a very poor prognosis (estimated 5-year survival rate of <16%). In the last few years, several drugs have been approved for malignant melanoma, such as tyrosine...

Full description

Bibliographic Details
Main Authors:	Kim, Ji Sung, Kim, Yong Guk, Pyo, Minji, Lee, Hong Kyung, Hong, Jin Tae, Kim, Youngsoo, Han, Sang-Bae
Format:	Online
Language:	English
Published:	The Korean Association of Immunologists 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411510/

id	pubmed-4411510
recordtype	oai_dc
spelling	pubmed-44115102015-04-28 Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells Kim, Ji Sung Kim, Yong Guk Pyo, Minji Lee, Hong Kyung Hong, Jin Tae Kim, Youngsoo Han, Sang-Bae Review Article Melanoma is the most aggressive skin cancer and its incidence is gradually increasing worldwide. Patients with metastatic melanoma have a very poor prognosis (estimated 5-year survival rate of <16%). In the last few years, several drugs have been approved for malignant melanoma, such as tyrosine kinase inhibitors and immune checkpoint blockades. Although new therapeutic agents have improved progression-free and overall survival, their use is limited by drug resistance and drug-related toxicity. At the same time, adoptive cell therapy of metastatic melanoma with tumor-infiltrating lymphocytes has shown promising results in preclinical and clinical studies. In this review, we summarize the currently available drugs for treatment of malignant melanoma. In addition, we suggest cytokine-induced killer (CIK) cells as another candidate approach for adoptive cell therapy of melanoma. Our preclinical study and several previous studies have shown that CIK cells have potent anti-tumor activity against melanomas in vitro and in an in vivo human tumor xenograft model without any toxicity. The Korean Association of Immunologists 2015-04 2015-04-23 /pmc/articles/PMC4411510/ /pubmed/25922594 http://dx.doi.org/10.4110/in.2015.15.2.58 Text en Copyright © 2015 The Korean Association of Immunologists http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Kim, Ji Sung Kim, Yong Guk Pyo, Minji Lee, Hong Kyung Hong, Jin Tae Kim, Youngsoo Han, Sang-Bae
spellingShingle	Kim, Ji Sung Kim, Yong Guk Pyo, Minji Lee, Hong Kyung Hong, Jin Tae Kim, Youngsoo Han, Sang-Bae Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells
author_facet	Kim, Ji Sung Kim, Yong Guk Pyo, Minji Lee, Hong Kyung Hong, Jin Tae Kim, Youngsoo Han, Sang-Bae
author_sort	Kim, Ji Sung
title	Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells
title_short	Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells
title_full	Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells
title_fullStr	Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells
title_full_unstemmed	Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells
title_sort	adoptive cell therapy of melanoma with cytokine-induced killer cells
description	Melanoma is the most aggressive skin cancer and its incidence is gradually increasing worldwide. Patients with metastatic melanoma have a very poor prognosis (estimated 5-year survival rate of <16%). In the last few years, several drugs have been approved for malignant melanoma, such as tyrosine kinase inhibitors and immune checkpoint blockades. Although new therapeutic agents have improved progression-free and overall survival, their use is limited by drug resistance and drug-related toxicity. At the same time, adoptive cell therapy of metastatic melanoma with tumor-infiltrating lymphocytes has shown promising results in preclinical and clinical studies. In this review, we summarize the currently available drugs for treatment of malignant melanoma. In addition, we suggest cytokine-induced killer (CIK) cells as another candidate approach for adoptive cell therapy of melanoma. Our preclinical study and several previous studies have shown that CIK cells have potent anti-tumor activity against melanomas in vitro and in an in vivo human tumor xenograft model without any toxicity.
publisher	The Korean Association of Immunologists
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411510/
_version_	1613216297604087808

Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells

Similar Items